On Course 2020:

Pipeline

Formerly called ME-401, zandelisib is a selective PI3K delta inhibitor which continues to display best-in-class potential in patients with B-cell malignancies.

People in an office building

Late-Stage Diversified Clinical Pipeline

Zandelisib
Oral P13K Delta Inhibitor
Indication Combination Phase 1/1B Phase 2 Phase 3 Commercial Rights
Follicular Lymphoma
Relapsed/refractory
Monotherapy
TIDAL: Accelerated Approval Study1
MEI pharma logo
kyowa kirin logo

U.S. co-promote; ex-U.S. Kyowa Kirin exclusive rights

Follicular Lymphoma
Relapsed/refractory

Monotherapy

Rituxan® (rituximab)

Zanubrutinib2 BeiGene logo

Clinical Collaboration
Voruciclib
Oral CDK Inhibitor
Indication Combination Phase 1/1B Phase 2 Phase 3 Commercial Rights
B-Cell Malignancies & AML
Relapsed/refractory

Monotherapy

Venclexta® (venetoclax)3

MEI pharma logo
ME-344
Mitochondrial Inhibitor
Indication Combination Phase 1/1B Phase 2 Phase 3 Commercial Rights
HER2-Breast Cancer
Treatment-naïve, early stage
Avastin® (bevacizumab)4
MEI pharma logo
Pracinostat
HDAC Inhibitor
Indication Combination Phase 1/1B Phase 2 Phase 3 Commercial Rights
Myelodysplastic Syndome
Treatment-naïve
Vidaza® (azacitidine)
Helsinn logo